https://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccineContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccine#u47142Mon, 24 Aug 2026 04:04:27 +0000Moderna shares more than doubled following the announcement of positive Phase III trial results for intismeran, an mRNA-based individualized neoantigen therapy developed with Merck. The trial involved more than 1,000 patients and demonstrated that the vaccine helped prevent the return and spread of melanoma. The news also triggered stock surges for several sequencing companies. This development marks the first-ever positive Phase III results for an mRNA cancer vaccine, potentially opening the door for a wider range of oncology treatments.Why it mattersMelanoma is the deadliest form of skin can https://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccine#u45998Fri, 21 Aug 2026 21:31:22 +0000Moderna's shares surged after its personalized mRNA cancer vaccine, developed with Merck, showed promise in a late-stage Phase III trial for melanoma. The vaccine aims to treat the deadliest form of skin cancer and could lead to broader mRNA-based oncology treatments. Both companies are preparing for a potential market debut of the therapy.Why it mattersThe success of the mRNA cancer vaccine could revolutionize cancer treatment and expand the use of mRNA technology in oncology. Moderna's stock has more than doubled, causing an estimated $5 billion loss for short sellers. The vaccine& https://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccinehttps://www.live-feeds.com/feed/moderna-shares-more-than-double-on-success-of-mrna-cancer-vaccine#u45757Fri, 21 Aug 2026 05:20:45 +0000Moderna shares rose sharply after a personalized mRNA cancer vaccine developed with Merck showed promise in a late-stage Phase III trial targeting melanoma. Market reactions varied by source, with reports of stock increases ranging from 90% to 177%, causing an estimated $5 billion loss for short sellers. The vaccine aims to treat the deadliest form of skin cancer and could lead to a broader wave of mRNA-based oncology treatments. Both companies are now preparing for a potential market debut of the therapy.Why it mattersThis development marks a shift for Moderna from COVID-19 vaccines toward pe